Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- XBI.MX
- Price
- -
- Stock movement up
- +- (%)
- Company name
- Exchange
- (MX ,
- Currency
- MXN )
- Market cap
- -
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -11.21%
- 3 year return
- -5.61%
- 5 year return
- -8.74%
- 10 year return
- 34.74%
Last updated: 2025-09-03
DIVIDENDS
XBI.MX does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| XBI.MX | S&P500 | |
| Current price drop from All-time high | -53.98% | - |
| Highest price drop | -96.80% | -56.47% |
| Date of highest drop | 11 Feb 2016 | 9 Mar 2009 |
| Avg drop from high | -44.29% | -10.99% |
| Avg time to new high | 28 days | 12 days |
| Max time to new high | 1137 days | 1805 days |
COMPANY DETAILS
Marketcap
-
Marketcap category
Mid-cap
Description
Employees
Investor relations
-
SEC filings
CEO
Country
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
We recently published 10 Trending Stocks This Week. SPDR S&P Biotech ETF (NYSEARCA:XBI) is one of the trending stocks this week. Joseph Terranova, Senior Managing Director, Virtus Investment Partners,...
October 21, 2025
Barron’s called Holz to ask about what’s happened to the biotech sector since our healthcare roundtable.
October 17, 2025
The Trump administration has promised to delay sector-specific tariffs for both firms, and more drugmakers could join the club.
October 13, 2025
Novo said it would buy Akero for $54 a share in cash and an additional $6 if it gets U.S. approval of efruxifermin, it’s treatment for fatty liver disease.
October 9, 2025
The SPDR S&P Biotech exchange-traded fund, which tracks a broad selection of biotech names, has shot up 8.9% since September 25, just more than a week ago. The biotech run-up over the past week or ...
October 6, 2025
Gilead looks attractive again. Its innovative edge and new crop of medications are performing well across multiple specialties.
October 2, 2025
AI's growing role in cancer research, and a new federal push for pediatric oncology, are powering gains in key healthcare ETFs.
October 1, 2025
Smart Beta ETF report for XBI
September 16, 2025
Investing.com -- RBC Capital said the potential departure of Health and Human Services Secretary Robert F. Kennedy Jr. could have wide-ranging implications for the biotech sector, with both winners an...
September 14, 2025
Next page